Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease
BioEssays · 2026-10 · 48 (10)
DOI: 10.1002/bies.70186 ↗At a glance
Übersichtsarbeit in BioEssays, published online on 2026-09-29. Written by Byungwook Kim and 3 co-authors. Institution: Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Alzheimer Disease, Microglia, Cellular Reprogramming. 86 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIA NIH HHS, Alzheimer's Association, NIGMS NIH HHS.
Topics: Demenz
Abstract (original language)
Recent human genetic studies revealed that Alzheimer's disease risk loci are enriched in genes expressed in myeloid cells, including microglia, the brain's resident immune cells. Notably, several risk‐associated genes, such as SPI1 and MEF2C , encode transcription factors (TFs) that control critical microglial functions, including phagocytosis, inflammatory responses, and neurotrophic support. The objective of this article is to review the recent progress in understanding these TFs and evaluate them as therapeutic targets rather than as markers of microglial state. We examine the genetic evidence implicating PU.1, MEF2C, IRF8, and BHLHE40/41, the in vivo evidence from animal models, the transcriptional network these factors regulate, and the barriers to clinical translation. Because these TFs orchestrate broad gene expression networks by regulating multiple disease‐relevant downstream partners, targeting their expression level or activity could achieve greater therapeutic efficacy than targeting single genes, provided that the dose and disease stage of modulation are carefully considered.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID profiles: Byungwook Kim, Selena S Wang, Justin R Kim, Jungsu Kim
Funding
- NIA NIH HHS
- Alzheimer's Association
- NIGMS NIH HHS
- National Science Foundation
Cite
APA
Kim, B., Wang, S. S., Kim, J. R., & Kim, J. (2026). Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease. BioEssays, 48(10). https://doi.org/10.1002/bies.70186
Vancouver
Kim B, Wang SS, Kim JR, Kim J. Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease. BioEssays. 2026;48(10). doi:10.1002/bies.70186
BibTeX
@article{Kim2026,
author = {Kim, Byungwook and Wang, Selena S and Kim, Justin R and Kim, Jungsu},
title = {Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease},
journal = {BioEssays},
year = {2026},
volume = {48},
number = {10},
doi = {10.1002/bies.70186}
}
EUVIMED